# AUVELITY (dextromethorphan-bupropion) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/dextromethorphan-bupropion

> The FDA approved AUVELITY (dextromethorphan-bupropion), sponsored by Axsome Therapeutics, Inc. (AXSM), on April 30, 2026 for agitation associated with dementia due to Alzheimer's disease.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is AUVELITY (dextromethorphan-bupropion) FDA approved?

Yes. The FDA approved AUVELITY (dextromethorphan-bupropion), sponsored by Axsome Therapeutics, Inc. (AXSM), on April 30, 2026 for agitation associated with dementia due to Alzheimer's disease. SEC Form 8-K: "On April 30, 2026, Axsome Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (FDA) has approved AUVELITY® for the treatment of agitation associated with dementia due to Alzheimer's disease." [Calendar and source filings](https://sec-api.dev/pdufa/dextromethorphan-bupropion)

Source: SEC Form 8-K, accession 0001193125-26-197857, https://www.sec.gov/Archives/edgar/data/1579428/000119312526197857/axsm-20260430.htm (retrieved 2026-11-12). Last confirmed 2026-11-02. Cite: https://sec-api.dev/pdufa/dextromethorphan-bupropion#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | AUVELITY (dextromethorphan-bupropion) |
| Codes | AXS-05 |
| Sponsor | Axsome Therapeutics, Inc. (AXSM) https://sec-api.dev/companies/axsm/catalysts |
| Indications | [agitation associated with dementia due to alzheimer's disease](https://sec-api.dev/indications/agitation-associated-with-dementia-due-to-alzheimer-s-disease), [central nervous system](https://sec-api.dev/indications/central-nervous-system), alzheimer's disease agitation, [smoking cessation](https://sec-api.dev/indications/smoking-cessation), ad agitation |
| Modality |  |
| FDA designations | breakthrough, fast track, orphan, priority review |

## Timeline

### Aug 2022: FDA approval

- Status: completed, approved. Date confidence: month. Indication: MDD in adults.
- First seen 2025-02-18, last confirmed 2025-02-18.
- SEC Form 10-K (accession 0000950170-25-022457): "In August 2022, Auvelity® was approved by the FDA for the treatment of MDD in adults and we initiated the commercial launch of Auvelity in the U.S. in October 2022." https://www.sec.gov/Archives/edgar/data/1579428/000095017025022457/axsm-20241231.htm

### Sep 2022: trial start

- Status: completed. Date confidence: month. Stage: 3. Indication: AD agitation.
- First seen 2025-02-18, last confirmed 2025-02-18.
- SEC Form 10-K (accession 0000950170-25-022457): "In September 2022, we initiated the ADVANCE-2 study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of AXS-05 in patients with AD agitation." https://www.sec.gov/Archives/edgar/data/1579428/000095017025022457/axsm-20241231.htm

### Q4 2024: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124546): "Topline results of ADVANCE-2 and ACCORD-2 Phase 3 trials of AXS-05 in Alzheimer's disease agitation on track for 4Q 2024" https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm

### Q3 2025: NDA/BLA submission

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Alzheimer's disease agitation.
- First seen 2024-12-30, last confirmed 2025-08-04.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-101624): "Supplemental NDA submission for AXS-05 in Alzheimer's disease agitation on track for 3Q 2025" https://www.sec.gov/Archives/edgar/data/1579428/000095017025101624/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063158): "Supplemental NDA submission for AXS-05 in Alzheimer's disease agitation on track for 3Q 2025" https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-021801): "Successful completion of Phase 3 clinical program of AXS-05 in Alzheimer's disease agitation announced; NDA submission anticipated in 2H 2025" https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-021801): "Based on the results from these studies, Axsome plans to submit a New Drug Application (NDA) for AXS-05 for the treatment of Alzheimer's disease agitation to the FDA in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-140949): "Axsome plans to submit an NDA for AXS-05 in Alzheimer's disease agitation to the FDA in the second half of 2025, based on the efficacy and safety data from the above controlled and long-term studies." https://www.sec.gov/Archives/edgar/data/1579428/000095017024140949/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-140949): "However, we are pleased with the very positive controlled safety data from this trial which will be an essential part of our planned NDA submission of AXS-05 in Alzheimer's disease agitation, which is targeted for the second half of 2025."" https://www.sec.gov/Archives/edgar/data/1579428/000095017024140949/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-140949): "Axsome plans to submit an NDA for AXS-05 in Alzheimer's disease agitation to the FDA in the second half of 2025, based on the efficacy and safety data from these studies." https://www.sec.gov/Archives/edgar/data/1579428/000095017024140949/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-101624): "Axsome is on track to submit the sNDA to the FDA in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017025101624/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063158): "The Company is on track to submit the sNDA in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-030395): "Axsome anticipates submitting the planned sNDA in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017025030395/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-030395): "We look to complete the sNDA submission in the third quarter of 2025, with the goal of making this important new potential therapy available to patients living with Alzheimer's disease as quickly as possible."" https://www.sec.gov/Archives/edgar/data/1579428/000095017025030395/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-140949): "The Company plans to submit a New Drug Application (NDA) to the FDA in 2H 2025" https://www.sec.gov/Archives/edgar/data/1579428/000095017024140949/axsm-ex99_1.htm

### Q4 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2/3.
- First seen 2024-11-12, last confirmed 2025-11-03.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-261651): "Smoking Cessation: Axsome plans to initiate a pivotal Phase 2/3 trial of AXS-05 in smoking cessation in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1579428/000119312525261651/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-101624): "Smoking Cessation: Axsome plans to initiate a pivotal Phase 2/3 trial of AXS-05 in smoking cessation in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017025101624/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063158): "Smoking Cessation: Axsome plans to initiate a pivotal Phase 2/3 trial of AXS-05 in smoking cessation in 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-021801): "Smoking Cessation: Axsome plans to initiate a pivotal Phase 2/3 trial of AXS-05 in smoking cessation in 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124546): "Smoking Cessation: Axsome plans to initiate a pivotal Phase 2/3 trial of AXS-05 in smoking cessation in 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm

### December 31, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: central nervous system.
- First seen 2025-12-31, last confirmed 2026-02-23.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-337644): "NEW YORK, December 31, 2025 (Globe Newswire) - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's supplemental New Drug Application (NDA) for AXS-05 (dextromethorphan HBr and bupropion HCl) for the treatment of Alzheimer's disease agitation, and has granted the application Priority Review designation." https://www.sec.gov/Archives/edgar/data/1579428/000119312525337644/axsm-ex99_2.htm
- SEC Form 10-K (accession 0001193125-26-064267): "In December 2025, the FDA accepted for filing the Company's supplemental NDA (sNDA) for AXS-05 for the treatment of Alzheimer's disease agitation." https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm
- SEC Form 10-K (accession 0001193125-26-064267): "In December 2025, the FDA accepted for filing the Company's supplemental New Drug Application (sNDA) for AXS-05 for the treatment of AD agitation and granted the application Priority Review designation." https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm

### April 30, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact. Indication: agitation associated with dementia due to Alzheimer's disease.
- First seen 2026-11-02, last confirmed 2026-11-02.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-442628): "AUVELITY was approved by the FDA for the treatment of agitation associated with dementia due to Alzheimer's disease on April 30, 2026 Acceleration in prescription trends among patients aged 65+ following ADA label expansion, alongside continued growth for under 65 FDA approval FDA approval" https://www.sec.gov/Archives/edgar/data/1579428/000119312526442628/axsm-ex99_2.htm

### April 30, 2026: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: agitation associated with dementia due to Alzheimer's disease.
- First seen 2026-04-30, last confirmed 2026-11-02.
- SEC Form 8-K (accession 0001193125-26-197857): "On April 30, 2026, Axsome Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (FDA) has approved AUVELITY® for the treatment of agitation associated with dementia due to Alzheimer's disease." https://www.sec.gov/Archives/edgar/data/1579428/000119312526197857/axsm-20260430.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-197857): "NEW YORK, April 30, 2026, (Globe Newswire) - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved AUVELITY® (dextromethorphan HBr and bupropion HCl) for the treatment of agitation associated with dementia due to Alzheimer's disease.1 AUVELITY is a first-in-class treatment for Alzheimer's disease agitation which targets the N-methyl D-aspartate (NMDA) and sigma-1 receptors." https://www.sec.gov/Archives/edgar/data/1579428/000119312526197857/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-197857): "Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease" https://www.sec.gov/Archives/edgar/data/1579428/000119312526197857/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-442628): "Continued NBRx acceleration to drive compounding TRx growth FDA approval FDA approval AUVELITY was approved by the FDA for the treatment of agitation associated with dementia due to Alzheimer's disease on April 30, 2026" https://www.sec.gov/Archives/edgar/data/1579428/000119312526442628/axsm-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-202506): "In April 2026, the U.S. Food and Drug Administration (FDA) approved AUVELITY for the treatment of agitation associated with dementia due to Alzheimer's disease." https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/axsm-ex99_1.htm

### April 30, 2026: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2025-12-31, last confirmed 2026-05-04.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-062421): "AXS-05 for Alzheimer's disease agitation, PDUFA target action (April 30, 2026)" https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-337644): "FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026" https://www.sec.gov/Archives/edgar/data/1579428/000119312525337644/axsm-ex99_2.htm
- SEC Form 10-Q (accession 0001193125-26-204274): "For instance, the FDA granted AXS-05 Priority Review on December 31, 2025, with a Prescription Drug User Fee Act (PDUFA) date of April 30, 2026, accelerating its review of Alzheimer's disease agitation; however, Priority Review does not guarantee FDA approval and could still lead to further data requests or denial." https://www.sec.gov/Archives/edgar/data/1579428/000119312526204274/axsm-20260331.htm
- SEC Form 10-K (accession 0001193125-26-064267): "For instance, the FDA granted AXS-05 Priority Review on December 31, 2025, with a Prescription Drug User Fee Act (PDUFA) date of April 30, 2026, accelerating its review of Alzheimer's disease agitation; however, Priority Review does not guarantee FDA approval and could still lead to further data requests or denial." https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-337644): "The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2026." https://www.sec.gov/Archives/edgar/data/1579428/000119312525337644/axsm-ex99_2.htm
- SEC Form 10-K (accession 0001193125-26-064267): "The application was granted Priority Review designation and a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2026." https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm
- SEC Form 10-K (accession 0001193125-26-064267): "The FDA has set a Prescription Drug User Fee Act (PDUFA) action goal date of April 30, 2026." https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm
- SEC Form 8-K (accession 0001193125-26-197857): "On April 30, 2026, Axsome Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (FDA) has approved AUVELITY® for the treatment of agitation associated with dementia due to Alzheimer's disease." https://www.sec.gov/Archives/edgar/data/1579428/000119312526197857/axsm-20260430.htm

### Q3 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2/3.
- First seen 2026-02-23, last confirmed 2026-08-10.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-341206): "Smoking Cessation: Axsome is on track to initiate a pivotal Phase 2/3 trial of AXS-05 in smoking cessation in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-202506): "Smoking Cessation: Axsome is on track to initiate a pivotal Phase 2/3 trial of AXS-05 in smoking cessation in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-062421): "Smoking Cessation: Axsome plans to initiate a pivotal Phase 2/3 trial of AXS-05 in smoking cessation in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-ex99_1.htm

### Aug 2026: trial start

- Status: completed. Date confidence: month. Stage: 3. Indication: smoking cessation.
- First seen 2026-11-02, last confirmed 2026-11-02.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-442628): "Smoking Cessation: In August 2026, Axsome initiated the SUMMIT study, a Phase 3, randomized, double-blind, active- and placebo-controlled, multicenter trial to assess the efficacy and safety of AXS-05 for the treatment of smoking cessation." https://www.sec.gov/Archives/edgar/data/1579428/000119312526442628/axsm-ex99_1.htm

## Same indication

- [SYMBRAVO® (meloxicam-rizatriptan)](https://sec-api.dev/pdufa/meloxicam-rizatriptan) (AXSM)
- [Reboxetine](https://sec-api.dev/pdufa/reboxetine) (AXSM)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/dextromethorphan-bupropion.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AUVELITY (dextromethorphan-bupropion) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/dextromethorphan-bupropion

```bibtex
@misc{secapidev_pdufa_dextromethorphan_bupropion_20261116,
  title        = {AUVELITY (dextromethorphan-bupropion) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/dextromethorphan-bupropion}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_dextromethorphan_bupropion_20261116","title":"AUVELITY (dextromethorphan-bupropion) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/dextromethorphan-bupropion","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
